Increased intracellular free Zn
INTRODUCTION
The heavy metal Zn 2ϩ is heterogeneously distributed throughout the brain, and regions such as the hippocampus contain large amounts of vesicular Zn 2ϩ (Frederickson, 1989) . Zn 2ϩ can be released into the synapse to modulate the activity of various neurotransmitter receptors; for example, Zn 2ϩ inhibits Nmethyl-d-aspartate (NMDA) and ␥-aminobutyric acid (GABA) receptors, and potentiates ␣-amino-5-hydroxy-3-methyl-4-isoxazole propionic acid (AMPA) receptors (Harrison & Gibbons, 1994; Smart et al., 1994) . Additionally, Zn 2ϩ inhibits transporter-mediated glutamate uptake (Vandenberg et al., 1998) and, depending on concentration, can inhibit or potentiate glycine receptors (Han & Wu, 1999; Spiridon et al., 1998) . While synaptic Zn 2ϩ may be important for normal neural function, it is also known that Zn 2ϩ is toxic to neurons. Numerous reports show that Zn 2ϩ is toxic to cultured neurons (Choi et al., 1988; Koh & Choi, 1988 , 1994 Manev et al., 1997; Weiss et al., 1993) , and studies in animal models suggest that endogenous Zn 2ϩ mediates neurodegeneration resulting from ischemia (Koh et al., 1996) and seizure (Suh et al., 1996) (Cheng & Reynolds, 1998; Sensi et al., 1997) . In addition, several plasma membrane transporters may mediate accumulation of [Zn 2ϩ ] i (Colvin, 1998; Gunshin et al., 1997; Palmiter & Findley, 1995 
